• Explore /
  • Poster
  • / Phase 3 KEYNOTE-905/EV-303: Perioperative pembrolizumab (pembro) or pembro + enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC).

Phase 3 KEYNOTE-905/EV-303: Perioperative pembrolizumab (pembro) or pembro + enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC).

Abstract Poster

Authors

Andrea Necchi

Andrea Necchi

Vita-Salute San Raffaele University; Department of Medical Oncology, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy

Andrea Necchi , Jens Bedke , Matt D. Galsky , Neal D. Shore , Elizabeth R. Plimack , Evanguelos Xylinas , Calvin Jia , Tammy Hennika , Blanca Homet Moreno , Alfred Alfred Witjes

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03924895

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr TPS585)

DOI

10.1200/JCO.2023.41.6_suppl.TPS585

Abstract #

TPS585

Poster Bd #

P8

Abstract Disclosures

Similar Posters

First Author: Andrea Necchi

First Author: Xiao X. Wei

First Author: Thomas W. Flaig

First Author: Christopher J. Hoimes